Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis
| Autor: | Maarten K. Ninaber, Suzana Jordan, Anna-Maria Hoffman-Vold, Oliver Distler, M. Boonstra, Tom W J Huizinga, Annette Grummels, René E. M. Toes, Hans Scherer, Jeska K de Vries-Bouwstra, Jaap A. Bakker, Corrie M. Wortel, Nina Ajmone Marsan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunology Full Length Systemic Sclerosis Gastroenterology Pulmonary function testing 03 medical and health sciences 0302 clinical medicine Immune system Rheumatology Internal medicine medicine Immunology and Allergy Humans 030212 general & internal medicine B cell Aged Autoantibodies 030203 arthritis & rheumatology Scleroderma Systemic biology business.industry Autoantibody Middle Aged medicine.disease Pulmonary hypertension Isotype Immunoglobulin Isotypes medicine.anatomical_structure DNA Topoisomerases Type I Immunoglobulin M Cohort biology.protein Disease Progression Female Antibody business |
| Zdroj: | Arthritis & Rheumatology (Hoboken, N.j.) Arthritis and Rheumatology, 72(11), 1897-1904. WILEY |
| ISSN: | 2326-5205 |
| Popis: | OBJECTIVE Anti-topoisomerase I (anti-topo I) autoantibodies in systemic sclerosis (SSc) are associated with diffuse skin involvement and interstitial lung fibrosis. Thus far, however, the relationship between anti-topo I antibody response and disease course has not yet been fully evaluated. This study was undertaken to gain insight into the association between characteristics of the anti-topo I antibody response and clinical disease course in SSc patients positive for anti-topo I antibodies. METHODS Levels of anti-topo I IgG, anti-topo I IgM, and anti-topo I IgA were assessed in consecutive serum samples obtained from patients at baseline who were positive for anti-topo I IgG in the Leiden Combined Care In Systemic Sclerosis (CCISS) cohort. One-year disease progression was defined by a relevant increase in modified Rodnan skin thickness score (MRSS), decline in pulmonary function, development of digital ulcers, renal crisis, and pulmonary hypertension, and/or mortality. Validation was performed in SSc patients who were positive for anti-topo I from the Oslo University Hospital and University Hospital Zurich. RESULTS Of the 103 patients with anti-topo I IgG in the CCISS cohort, clinical data were available to assess 1-year disease progression in 81 patients. Of these 81 patients, 23 (28%) had disease progression. At baseline, patients with disease progression were significantly more often anti-topo I IgM-positive than those who did not experience disease progression (21 [91%] of 23 versus 33 [57%] of 58; P < 0.01). This finding was confirmed in the independent validation samples. CONCLUSION In SSc patients who were anti-topo I IgG-positive, presence of anti-topo I IgM, which might be considered as a surrogate for an ongoing autoreactive B cell immune response, is associated with disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text